

Network Provider Update

To: Medi-Cal Network Participants

November 2021

From: Susan Nakahiro, Director *Susan Nakahiro*
Pharmacy Benefit and Claims Operations

Subject: Medi-Cal Drug Utilization Review (DUR) Program Educational Articles and Alerts

The Medi-Cal Drug Utilization Review (DUR) Program issues educational articles and alerts with information to improve the quality and cost-effectiveness of prescribing and dispensing practices for Medi-Cal recipients.¹ Blue Shield of California Promise Health Plan will notify you periodically about these articles so that you can apply the information to your practice or facility, as appropriate.

For your convenience, we are including links to updates posted by the Medi-Cal DUR Program on their website.

1. [2021 Immunization Updates: COVID-19, Influenza, and Meningococcal Disease](#)
2. [UPDATED: Drug Safety Communication: Voluntary Recall of Varenicline \(Chantix\) Due to Nitrosamine](#)
3. [Drug Safety Communication: FDA Requests Removal of Pregnancy Contraindication for Statins](#)

All Medi-Cal DUR Program Educational Bulletins are available on the Department of Health Care Services (DHCS) Medi-Cal [website](#).

*We also recommend this article from the California Department of Public Health:

[Best Practices for Providers Who Inherit Patients on Opioids](#)

If you have questions about drug utilization for Blue Shield Promise members, please call our Provider Services Department at **(800) 468-9935** from 6 a.m. to 6:30 p.m., Monday through Friday.

¹ These articles are the result of analyses carried out by the Global Medi-Cal DUR Program and are not official policies of the Department of Health Care Services (DHCS).

TBSP12271 (11/21)

Prov_21_198